The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
The new generation of weight-loss drugs were initially developed to treat diabetes and work by mimicking a hormone that ...
From emergency room visits to dangerous weight loss, celebrities are speaking out about severe complications from the popular ...
Healthcare groups are reacting to Novo Nordisk's recent petition to the FDA to prevent compounding pharmacies from producing unapproved — and often cheaper — versions of weight loss injection Wegovy ...
Ozempic and other GLP-1 drugs have surged in popularity, dominating U.S. medication spending in 2023 for their effectiveness in managing diabetes and promoting weight loss. As demand grows, promising ...
A doctor, bariatric surgeon and professor say that treatments other than weight-loss drugs are needed to fix the obesity ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.